Примери за използване на Sponsor shall notify на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The sponsor shall notify the Member States concerned, through the EU portal, of the event and the measures taken.
When a temporarily halted clinical trial referred to in paragraph 5 is resumed the sponsor shall notify each Member State concerned through the EU portal.
The sponsor shall notify each Member State concerned of the end of a clinical trial in all Member States concerned through the EU portal.
If the investigation is conducted in more than one Member State the sponsor shall notify all Member States concerned of the overall end of the clinical investigation.
The sponsor shall notify each Member State concerned of the end of a clinical trial in relation to that Member State through the EU portal.
In the case of early termination of the clinical trial for reasons not affecting the benefit-risk balance, the sponsor shall notify each Member State concerned through the EU portal of the reasons for such action and, when appropriate, follow-up measures for the subjects.
The sponsor shall notify each Member State concerned of the first visit of the first subject in relation to that Member State through the EU portal.
If a study is conducted in more than one Member State, the sponsor shall notify all Member States in which that performance study was conducted of the end of the performance study in all Member States.
The sponsor shall notify each Member State in which a clinical investigation was being conducted of the end of that clinical investigation in that Member State.
If the investigation is conducted in more than one Member State the sponsor shall notify all Member States concerned of the early termination in one Member State and of the overall end of the clinical investigation.
The sponsor shall notify the Member States concerned through the EU portal of all unexpected events which affect the benefit-risk balance of the clinical trial, but are not suspected unexpected serious adverse reactions as referred to in Article 42.
If an investigation is conducted in more than one Member State, the sponsor shall notify all Member States in which that clinical investigation was conducted of the end of the clinical investigation in all Member States.
The sponsor shall notify each Member State concerned of the end of the recruitment of subjects for a clinical trial in that Member State through the EU portal.
The sponsor shall notify each Member State concerned of a temporary halt of a clinical trial in all Member States concerned for reasons not affecting the benefit-risk balance through the EU portal.
The sponsor shall notify each Member State concerned of the end of a clinical trial in all Member States concerned and in all third countries in which the clinical trial has been conducted through the EU portal.
The sponsor shall notify the Member States concerned about a serious breach of this Regulation or of the version of the protocol applicable at the time of the breach through the EU portal without undue delay but not later than seven days of becoming aware of that breach.
The Member State shall notify the sponsor of the authorisation within 45 days of the validation date of the application referred to in paragraph 5.
Within six days from the submission of the application dossier,the Member State concerned shall notify the sponsor through the EU portal of the following.
Each Member State concerned shall notify the sponsor through the EU portal as to whether the substantial modification is authorised, whether it is authorised subject to conditions, or whether authorisation is refused.
Each Member State concerned shall notify the sponsor through the EU portal as to whether the clinical trial is authorised, whether it is authorised subject to conditions, or whether authorisation is refused.
(c) within 10 days of the notification date, assess whether the clinical investigation falls within the scope of this Regulation andwhether the application is complete, and shall notify the sponsor accordingly.
Each Member State concerned shall notify the sponsor through the electronic system referred to in Article 69 as to whether the performance study is authorised, whether it is authorised subject to conditions, or whether authorisation has been refused.
The Member State concerned shall notify the sponsor within five days of receipt of the comments or of the requested additional information, whether the clinical investigation is considered as falling within the scope of this Regulation and the application is complete.
Within five days from receipt of the comments orthe completed application dossier, the reporting Member State shall notify the sponsor as to whether or not the application complies with the requirements set out in points(a) and(b) of paragraph 2.
Within 10 days of receiving the application, the Member State concerned shall notify the sponsor as to whether the performance study falls within the scope of this Regulation and as to whether the application dossier is complete in accordance with Chapter I of Annex XIV.
In the case of amendments to Regulation 1 of the SAC, leading to a higher legal fees,the lawyer shall notify the sponsor of the new conditions on its tariffs by sending new tariff and is obliged to fulfill its obligations under the contract and the previous tariff one month after notification to the contracting authority.
On the basis of a written request by the sponsor, with the acceptance of the applicant,the determining Member State shall notify the Member State where the sponsor is established of the sponsorship agreement between the organisation and the applicant.
If a sponsor intends to introduce modifications to a clinical investigation that are likely to have a substantial impact on the safety, health or rights of the subjects or on the robustness or reliability of the clinical data generated by the investigation, it shall notify, within one week, by means of the electronic system referred to in Article 73 the Member State(s) in which the clinical investigation is being or is to be conducted of the reasons for and the nature of those modifications.
The sponsor or his Authorized Representative shall notify the competent authorities in the relevant member states concerned of the end of the clinical study, with a justification in case of early termination.
Where the Member State has not notified the sponsor within the time period referred to in the first subparagraph, the clinical investigation shall be considered as falling within the scope of this Regulation and the application shall be considered complete.